Aeglea BioTherapeutics | Mergers and Acquisitions Presentation Deck | 50 slides · page 23 of 50
The chart combines a bar chart of competitor benchmarks with a bar chart showing vedolizumab's exposure-response quartiles.
Deck · problem_statement · frame_problem · overcrowded density
Slide locked Sign in to view
Slide schematic 6/6
callout 1/1 chart 1/1 list 2/2 source-note 1/1 title 1/1
Components 6
primary bar-vertical bullet bullet source-note headline
Tools 1
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1